Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Indivior Pharmaceuticals Inc

INDV ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Mid Cap Analyst: BUY

Last Close

$39.01

▲ +2.07%

Market Cap $4.60B · Vol 291.91K

Key Metrics

P/E Ratio

14.04

FWD: 13.21

Market Cap

$4.60B

Mid Cap

Div Yield

N/A

EPS Growth

+76.35%

YoY

RSI (14)

44.96

Momentum

Beta

N/A

vs Market

52W High

$42.78

8.81% below

52W Low

$22.27

75.17% above

Volume

291.91K

Avg 649.30K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

97.99%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Indivior Pharmaceuticals Inc (INDV) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does INDV pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.49%

-3.03%

+3.12%

+12.81%

YTD

+8.72%

+68.36%

+71.70%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$1.24B
Net Income	$210.00M
Revenue Growth (YoY)	+13.58%
Gross Margin	84.10%
Operating Margin	25.34%
Net Profit Margin	16.95%
ROE	N/A
ROA · ROIC	18.99% · 229.99%

P/E Ratio	14.04
Forward P/E (FY1)	13.21
PEG Ratio	0.01
P/S	3.71
P/B	N/A
P/FCF	N/A
EPS Growth	+76.35%
Outstanding Shares	118.01M

Technical Indicators

50-Day SMA	$39.49
200-Day SMA	$35.15
RSI (14)	44.96
Beta	N/A
52-Week High	$42.78
52-Week Low	$22.27

Volume Today	291.91K
Avg Daily Volume (30D)	649.30K
Relative Volume	0.45x
Volatility (10D)	48.53
Volatility (30D)	34.71
Free Float	97.99%

Analyst Consensus

BUY

Current Price $39.01

Mean Target $49.00

52W Low$22.27 52W High$42.78

Current

Target

$22.27 $42.78

Current Analyst target

+25.61% upside potential · 4 analysts

Identifiers

ExchangeNasdaq

FIGIBBG003T4KGV1

ISINUS45579U1097

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 3, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.